FDA Approves Generic Lidocaine Ointment

Article

SunGen Pharma, the specialty pharmaceutical company, has received its eighth ANDA approval from the FDA.

SunGen Pharma has received FDA approval for an abbreviated new drug application approval for Lidocaine Ointment USP, 5%. The drug product is used for the production of anesthesia of accessible mucous membranes of the oropharynx.

The product is also used as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites.

Lidocaine has annual sales of about $60 million.

REFERENCE

SunGen Pharma receives eighth ANDA approval from US FDA [news release]. Princeton, NJ; October 31, 2019: Globe Newswire. https://www.globenewswire.com/news-release/2019/10/31/1939048/0/en/SunGen-Pharma-Receives-Eighth-ANDA-Approval-from-US-FDA.html. Accessed October 31, 2019.

Recent Videos
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Image Credit: © Anastasiia - stock.adobe.com
Image Credit: © Анастасія Стягайло - stock.adobe.com
breast cancer treatment/Image Credit: © Siam - stock.adobe.com
small cell lung cancer treatment/Image Credit: © CraftyImago - stock.adobe.com